Hinge Health, Inc. (HNGE): what the price assumes

In the published model solve dated 2026-Q2, anchored at $80.73, Hinge Health, Inc. (HNGE) is priced for today's economics sustained for ~6.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/HNGE

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 9.2% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.8 years.

How unusual the bet is: elevated (limited comparison data)

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=7)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

• Hinge Health sells digital musculoskeletal care to employers and health plans on an annual subscription where, per its 10-K, clients only pay for members that engage with our programs, so engagement is both the product and the revenue lever.
• The defining recent fact is the profitability inflection: Q1 2026 revenue grew 47% to $182 million with an 85% gross margin and a 25% operating margin, and free cash flow turned to $42 million, a tenfold jump year over year.
• The biggest risk is durability of that growth at a rich price; the stock trades around 8.5 times revenue, and the company itself warns it has a history of net losses and may not maintain profitability, so the next several quarters of billings and client adds are what to watch.

Bull Case

The balance sheet is what turns Hinge Health from a speculative growth story into an investable one. The company holds roughly $405 million of cash and carries no debt, and it is no longer burning that cash, it is adding to it. Free cash flow in Q1 2026 was $42 million, a tenfold increase year over year at a 23% margin. A young health-technology company that has reached self-funding profitability removes the single biggest risk that sinks most of its cohort: the need to return to capital markets on someone else's terms. Hinge can fund its own growth.

The growth itself is both fast and increasingly profitable, a rare combination. Q1 2026 revenue rose 47% to $182 million, ahead of guidance, while gross margin reached 85% and operating margin hit 25%, up from 12% a year earlier, driven by AI and automation efficiencies. Calculated billings, the leading indicator of future revenue, grew 52% to $770 million over the trailing twelve months. The economics are attractive because the model is a recurring subscription recognized ratably; the 10-K notes revenue is recognized ratably over the 12 months after an eligible life becomes a member, which gives the business visibility and a base that compounds as clients add lives.

The platform is broadening beyond its musculoskeletal core. The company launched a migraine program built on its FDA-cleared Enso device and reported rapid adoption, over 125 clients and 2 million eligible lives within weeks. Each new condition the platform addresses extends the value of an existing client relationship without proportionally more sales effort, the classic land-and-expand dynamic. Management raised full-year 2026 guidance to $798 to $804 million of revenue and $205 to $215 million of operating income. The bull case is a profitable, self-funding, fast-growing platform expanding its addressable conditions, no longer dependent on the capital markets to keep going.

Bear Case

The structural truth a holder should keep in view is that Hinge Health is a young company whose recent profitability is new and whose trailing record is one of losses. The company says so itself, leading its risk factors with the plain admission that it has a history of net losses, we anticipate increasing expenses in the future, and we may not be able to maintain profitability. The most recent quarter looks excellent, but it is a few quarters of strength against a longer history of red ink, and the trailing full-year operating result remains negative once the costs of going public are counted. Extrapolating the latest 25% operating margin as the durable norm is a bet on a turn that is only just beginning.

The revenue model carries a quieter vulnerability: it is paid only for engaged members. That is a feature when engagement is high, but it means revenue is not contracted on signed lives alone; it depends on people actually using the program, month after month. The 10-K frames the whole business around the ability to maintain and increase our contracted lives and members and the revenue from them. Digital-health engagement is notoriously hard to sustain past the early enthusiasm, and a dip in usage flows straight to the top line in a way a fixed-fee contract would not. The migraine launch is promising, but adoption in weeks is not the same as retention over years.

The price leaves no cushion for any of this. At about 8.5 times revenue, the stock implies revenue compounding around 22.5% a year while the business eventually earns an operating margin near 32%, a combination only about 38% of comparable fast-growers sustained for five years. Only the forward-growth lens reaches the current price; the earnings-power and peer-multiple methods both read it as richly valued, because there is no settled earnings base to anchor on. A high-growth platform priced for durable compounding has two ways to disappoint: growth decelerates, or the new margins prove cyclical rather than structural. The bear case is that Hinge is being valued as if the inflection is permanent when the company's own filing says profitability is not assured.

Valuation

Because Hinge Health does not yet have a settled operating-profit history, the price is read against sales rather than earnings, and at roughly 8.5 times revenue it is a clear growth premium. The inversion translates that multiple into two linked assumptions: revenue growing about 22.5% a year for several years, and the business eventually earning an operating margin near 32%. The recent results make both look plausible rather than fanciful, Q1 2026 revenue grew 47% and operating margin already reached 25%, but the price requires that trajectory to hold for years, and only about 38% of comparable fast-growers managed it.

The families of method line up exactly as they do for a richly priced growth name. Only the forward-growth lens reaches the current price; the earnings-power and peer-multiple approaches both read the stock as expensive, and there is no asset-based floor to speak of because the value is the platform and the client relationships, not tangible assets. When only the growth lens reaches the price, the premium is a pure durability bet: the static methods structurally cannot price a business whose value is almost entirely forward.

The one unambiguous strength is the balance sheet. Roughly $405 million of cash, no debt, and positive free cash flow mean the company is self-funding, which removes the dilution-and-distress risk that usually accompanies an 8.5-times-revenue valuation. One measurement note: the trailing operating income read from the annual filing is sharply negative, reflecting public-offering and stock-compensation costs, while the most recent quarter is solidly profitable, so the trailing-loss figure and the current run rate are different bases and should not be blended. The valuation comes down to a single judgment: whether the recent inflection in growth and margin is the new structural reality the price assumes, or an early-stage high that has yet to prove it can persist.

Catalysts

The Q1 2026 report, reported in early May, was a broad beat-and-raise. Revenue of $182 million grew 47% year over year and topped the $171 to $173 million guidance, gross margin reached 85%, and operating margin hit 25% for $46 million of operating income, ahead of the guided $30 to $32 million. Free cash flow of $42 million was up tenfold, and calculated billings grew 52% to $770 million over the trailing twelve months, with the commercial pipeline described as substantially larger than a year earlier and the small-business pipeline more than doubling.

Two forward threads matter most. First, product expansion: the migraine program built on the FDA-cleared Enso device drew over 125 clients and 2 million eligible lives within weeks of launch, an early read on whether Hinge can extend beyond musculoskeletal care into a multi-condition platform. Second, the raised outlook: Q2 revenue guidance of $194 to $196 million implies roughly 40% growth at the midpoint, and full-year 2026 guidance was lifted to $798 to $804 million of revenue and $205 to $215 million of operating income. The clearest checkpoints ahead are whether billings growth holds near the 50% range, whether member engagement sustains the revenue the model depends on, and whether the migraine adoption converts from fast sign-ups into durable, retained usage.

Peer Cohorts (Per Segment, With Filing Citations)

Hinge Health (consolidated) (reported)

• DOCS (Doximity, Inc.)
• FY2025 10-K: …careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers primarily include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow…
• FY2025 10-K: …to articles about scientific congresses or professional meetings. We take a rigorous approach to launching new modules, including internal and customer pilots. Our goal is to make sponsored content useful, relevant, and informative for our members. Our newer integrated programs allow our clients to leverage the power…
• HIMS (HIMS & HERS HEALTH, INC.)
• FY2025 10-K: …to consolidated financial statements. 89 Table of Contents Hims & Hers Health, Inc. Notes to Consolidated Financial Statements 1. Organization Hims & Hers Health, Inc. (the "Company" or "Hims & Hers"), incorporated in Delaware, is a consumer-first platform transforming the way customers fulfill their health and…
• FY2025 10-K: …reference. 130 Table of Contents PART IV Item 15. Exhibits and Financial Statement Schedules See "Index to Consolidated Financial Statements" in Part II, Item 8 of this Annual Report on Form 10-K. Financial statement schedules have been omitted because they are not required or are not applicable or because the…
• PGNY (Progyny, Inc.)
• FY2025 10-K: …formulary plan design, simplified authorization, assistance with prescription fulfillment, and timely delivery of the medications by the Company's network of specialty pharmacies, as well as medication administration training, pharmacy support services, and continuing PCA support. As a pharmacy benefits solution…
• FY2025 10-K: …the (i) S&P Health Care (Sector) and (ii) the Nasdaq Composite Index. Each index assumes an initial investment of $100 in each and, assumes the reinvestment of any dividends, based on closing prices. Cumulative Total Returns Company/Index 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025 Progyny, Inc.…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.